Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Repeated Intraarterial Bevacizumab Plus Carboplatin for Relapsed/Refractory GBM and AA
NCT01386710Phase 2Suspended
- Sponsor
- Northwell Health
- Start
- Sep 2011
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bevacizumab and carboplatin in glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA) (2 arms), sponsored by Northwell Health. Primary endpoints: Composite Overall Response Rate at 6 months, Progression-Free Survival at 2 years and 1 more. Started Sep 2011; status: suspended.
02
Drugs
bevacizumabcarboplatin
03
Conditions
glioblastoma multiforme (GBM)anaplastic astrocytoma (AA)
Beyond the preview
Go deeper on NCT01386710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01386710.